Detailed longitudinal sampling of glioma stem cells in situ reveals Chr7 gain and Chr10 loss as repeated events in primary tumor formation and recurrence

Mehmet Baysan, Kevin Woolard, Margaret C. Cam, Wei Zhang, Hua Song, Svetlana Kotliarova, Demosthenes Balamatsias, Amanda Linkous, Susie Ahn, Jennifer Walling, Galina I. Belova, Howard A. Fine

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Intratumoral heterogeneity at the genetic, epigenetic, transcriptomic, and morphologic levels is a commonly observed phenomenon in many aggressive cancer types. Clonal evolution during tumor formation and in response to therapeutic intervention can be predicted utilizing reverse engineering approaches on detailed genomic snapshots of heterogeneous patient tumor samples. In this study, we developed an extensive dataset for a GBM case via the generation of polyclonal and monoclonal glioma stem cell lines from initial diagnosis, and from multiple sections of distant tumor locations of the deceased patient's brain following tumor recurrence. Our analyses revealed the tissue-wide expansion of a new clone in the recurrent tumor and chromosome 7 gain and chromosome 10 loss as repeated genomic events in primary and recurrent disease. Moreover, chromosome 7 gain and chromosome 10 loss produced similar alterations in mRNA expression profiles in primary and recurrent tumors despite possessing other highly heterogeneous and divergent genomic alterations between the tumors. We identified ETV1 and CDK6 as putative candidate genes, and NFKB (complex), IL1B, IL6, Akt and VEGF as potential signaling regulators, as potentially central downstream effectors of chr7 gain and chr10 loss. Finally, the differences caused by the transcriptomic shift following gain of chromosome 7 and loss of chromosome 10 were consistent with those generally seen in GBM samples compared to normal brain in large-scale patient-tumor data sets.

Original languageEnglish (US)
Pages (from-to)2002-2013
Number of pages12
JournalInternational Journal of Cancer
Volume141
Issue number10
DOIs
StatePublished - Nov 15 2017

Fingerprint

Glioma
Stem Cells
Recurrence
Chromosomes, Human, Pair 10
Chromosomes, Human, Pair 7
Neoplasms
Clonal Evolution
Tissue Expansion
Genetic Heterogeneity
Epigenomics
Brain Neoplasms
Vascular Endothelial Growth Factor A
Interleukin-6
Clone Cells
Cell Line
Messenger RNA
Brain
Genes

Keywords

  • clonal development
  • glioblastoma
  • glioma stem cells
  • intratumor heterogeneity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Detailed longitudinal sampling of glioma stem cells in situ reveals Chr7 gain and Chr10 loss as repeated events in primary tumor formation and recurrence. / Baysan, Mehmet; Woolard, Kevin; Cam, Margaret C.; Zhang, Wei; Song, Hua; Kotliarova, Svetlana; Balamatsias, Demosthenes; Linkous, Amanda; Ahn, Susie; Walling, Jennifer; Belova, Galina I.; Fine, Howard A.

In: International Journal of Cancer, Vol. 141, No. 10, 15.11.2017, p. 2002-2013.

Research output: Contribution to journalArticle

Baysan, M, Woolard, K, Cam, MC, Zhang, W, Song, H, Kotliarova, S, Balamatsias, D, Linkous, A, Ahn, S, Walling, J, Belova, GI & Fine, HA 2017, 'Detailed longitudinal sampling of glioma stem cells in situ reveals Chr7 gain and Chr10 loss as repeated events in primary tumor formation and recurrence', International Journal of Cancer, vol. 141, no. 10, pp. 2002-2013. https://doi.org/10.1002/ijc.30887
Baysan, Mehmet ; Woolard, Kevin ; Cam, Margaret C. ; Zhang, Wei ; Song, Hua ; Kotliarova, Svetlana ; Balamatsias, Demosthenes ; Linkous, Amanda ; Ahn, Susie ; Walling, Jennifer ; Belova, Galina I. ; Fine, Howard A. / Detailed longitudinal sampling of glioma stem cells in situ reveals Chr7 gain and Chr10 loss as repeated events in primary tumor formation and recurrence. In: International Journal of Cancer. 2017 ; Vol. 141, No. 10. pp. 2002-2013.
@article{ddf6c5aa90174324b4f1752f44ba7389,
title = "Detailed longitudinal sampling of glioma stem cells in situ reveals Chr7 gain and Chr10 loss as repeated events in primary tumor formation and recurrence",
abstract = "Intratumoral heterogeneity at the genetic, epigenetic, transcriptomic, and morphologic levels is a commonly observed phenomenon in many aggressive cancer types. Clonal evolution during tumor formation and in response to therapeutic intervention can be predicted utilizing reverse engineering approaches on detailed genomic snapshots of heterogeneous patient tumor samples. In this study, we developed an extensive dataset for a GBM case via the generation of polyclonal and monoclonal glioma stem cell lines from initial diagnosis, and from multiple sections of distant tumor locations of the deceased patient's brain following tumor recurrence. Our analyses revealed the tissue-wide expansion of a new clone in the recurrent tumor and chromosome 7 gain and chromosome 10 loss as repeated genomic events in primary and recurrent disease. Moreover, chromosome 7 gain and chromosome 10 loss produced similar alterations in mRNA expression profiles in primary and recurrent tumors despite possessing other highly heterogeneous and divergent genomic alterations between the tumors. We identified ETV1 and CDK6 as putative candidate genes, and NFKB (complex), IL1B, IL6, Akt and VEGF as potential signaling regulators, as potentially central downstream effectors of chr7 gain and chr10 loss. Finally, the differences caused by the transcriptomic shift following gain of chromosome 7 and loss of chromosome 10 were consistent with those generally seen in GBM samples compared to normal brain in large-scale patient-tumor data sets.",
keywords = "clonal development, glioblastoma, glioma stem cells, intratumor heterogeneity",
author = "Mehmet Baysan and Kevin Woolard and Cam, {Margaret C.} and Wei Zhang and Hua Song and Svetlana Kotliarova and Demosthenes Balamatsias and Amanda Linkous and Susie Ahn and Jennifer Walling and Belova, {Galina I.} and Fine, {Howard A.}",
year = "2017",
month = "11",
day = "15",
doi = "10.1002/ijc.30887",
language = "English (US)",
volume = "141",
pages = "2002--2013",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Detailed longitudinal sampling of glioma stem cells in situ reveals Chr7 gain and Chr10 loss as repeated events in primary tumor formation and recurrence

AU - Baysan, Mehmet

AU - Woolard, Kevin

AU - Cam, Margaret C.

AU - Zhang, Wei

AU - Song, Hua

AU - Kotliarova, Svetlana

AU - Balamatsias, Demosthenes

AU - Linkous, Amanda

AU - Ahn, Susie

AU - Walling, Jennifer

AU - Belova, Galina I.

AU - Fine, Howard A.

PY - 2017/11/15

Y1 - 2017/11/15

N2 - Intratumoral heterogeneity at the genetic, epigenetic, transcriptomic, and morphologic levels is a commonly observed phenomenon in many aggressive cancer types. Clonal evolution during tumor formation and in response to therapeutic intervention can be predicted utilizing reverse engineering approaches on detailed genomic snapshots of heterogeneous patient tumor samples. In this study, we developed an extensive dataset for a GBM case via the generation of polyclonal and monoclonal glioma stem cell lines from initial diagnosis, and from multiple sections of distant tumor locations of the deceased patient's brain following tumor recurrence. Our analyses revealed the tissue-wide expansion of a new clone in the recurrent tumor and chromosome 7 gain and chromosome 10 loss as repeated genomic events in primary and recurrent disease. Moreover, chromosome 7 gain and chromosome 10 loss produced similar alterations in mRNA expression profiles in primary and recurrent tumors despite possessing other highly heterogeneous and divergent genomic alterations between the tumors. We identified ETV1 and CDK6 as putative candidate genes, and NFKB (complex), IL1B, IL6, Akt and VEGF as potential signaling regulators, as potentially central downstream effectors of chr7 gain and chr10 loss. Finally, the differences caused by the transcriptomic shift following gain of chromosome 7 and loss of chromosome 10 were consistent with those generally seen in GBM samples compared to normal brain in large-scale patient-tumor data sets.

AB - Intratumoral heterogeneity at the genetic, epigenetic, transcriptomic, and morphologic levels is a commonly observed phenomenon in many aggressive cancer types. Clonal evolution during tumor formation and in response to therapeutic intervention can be predicted utilizing reverse engineering approaches on detailed genomic snapshots of heterogeneous patient tumor samples. In this study, we developed an extensive dataset for a GBM case via the generation of polyclonal and monoclonal glioma stem cell lines from initial diagnosis, and from multiple sections of distant tumor locations of the deceased patient's brain following tumor recurrence. Our analyses revealed the tissue-wide expansion of a new clone in the recurrent tumor and chromosome 7 gain and chromosome 10 loss as repeated genomic events in primary and recurrent disease. Moreover, chromosome 7 gain and chromosome 10 loss produced similar alterations in mRNA expression profiles in primary and recurrent tumors despite possessing other highly heterogeneous and divergent genomic alterations between the tumors. We identified ETV1 and CDK6 as putative candidate genes, and NFKB (complex), IL1B, IL6, Akt and VEGF as potential signaling regulators, as potentially central downstream effectors of chr7 gain and chr10 loss. Finally, the differences caused by the transcriptomic shift following gain of chromosome 7 and loss of chromosome 10 were consistent with those generally seen in GBM samples compared to normal brain in large-scale patient-tumor data sets.

KW - clonal development

KW - glioblastoma

KW - glioma stem cells

KW - intratumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=85029592915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029592915&partnerID=8YFLogxK

U2 - 10.1002/ijc.30887

DO - 10.1002/ijc.30887

M3 - Article

C2 - 28710771

AN - SCOPUS:85029592915

VL - 141

SP - 2002

EP - 2013

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 10

ER -